https://pyxisoncology.com/resource/a-pilot-study-to-evaluate-the-clinical-and-immunological-effects-of-incorporating-a-cd40-agonistic-antibody-into-the-multimodality-treatment-of-resectable-esophageal-and-ge-junction-cancersrcoma/ 2023-08-30T10:31:20+00:00 https://pyxisoncology.com/resource/phase-1-study-to-evaluate-the-safety-and-tolerability-of-the-cd40-agonistic-monoclonal-antibody-apx005m-in-subjects-with-solid-tumors/ 2023-08-30T10:31:57+00:00 https://pyxisoncology.com/resource/a-phase-ib-ii-study-of-cd40-agonistic-monoclonal-antibody-apx005m-together-with-gemcitabine-and-nab-paclitaxel-with-or-without-nivolumabin-untreated-metastatic-pancreatic-adenocarcinoma-patients/ 2023-08-30T10:32:31+00:00 https://pyxisoncology.com/resource/a-study-to-evaluate-the-safety-and-efficacy-of-the-cd40-agonistic-antibody-apx005m-administered-in-combination-with-nivolumab-in-subjects-with-non-small-cell-lung-cancer-and-subjects-with-metastatic-m/ 2023-08-30T10:33:23+00:00 https://pyxisoncology.com/resource/first-in-human-study-with-the-cd40-agonistic-monoclonal-antibody-apx005m-in-subjects-with-solid-tumors/ 2023-08-30T10:33:57+00:00 https://pyxisoncology.com/resource/a-phase-1b-study-of-cd40-agonistic-monoclonal-antibody-apx005m-together-with-gemcitabine-and-nab-paclitaxel-with-or-without-nivolumab-in-untreated-metastatic-ductal-pancreatic-adenocarcinoma-pdac-pa/ 2023-08-30T10:35:32+00:00 https://pyxisoncology.com/resource/a-phase-1b-study-of-cd40-agonistic-monoclonal-antibody-apx005m-together-with-gemcitabine-and-nab-paclitaxel-with-or-without-nivolumab-in-untreated-metastatic-pancreatic-ductal-adenocarcinoma-pdac-pa/ 2023-08-30T10:36:19+00:00 https://pyxisoncology.com/resource/phase-1b-2-study-of-cd40-agonistic-antibody-apx005m-in-combination-with-nivolumab-nivo-in-subjects-with-metastatic-melanoma-m-and-subjects-with-non-small-cell-lung-cancer-nsclc/ 2023-08-30T10:36:53+00:00 https://pyxisoncology.com/resource/a-phase-ii-trial-with-a-safety-lead-in-to-evaluate-the-addition-of-apx005m-a-cd40-agonistic-monoclonal-antibody-to-standard-of-care-doxorubicin-for-the-treatment-of-patients-with-advanced-sarcoma/ 2023-08-30T10:38:06+00:00 https://pyxisoncology.com/resource/first-in-pediatrics-phase-1-study-of-cd40-agonistic-monoclonal-antibody-apx005m-in-pediatric-subjects-with-recurrent-refractory-brain-tumors/ 2023-08-30T10:38:49+00:00 https://pyxisoncology.com/resource/gemcitabine-and-nab-paclitaxel-±-nivolumab-±-cd40-agonistic-monoclonal-antibody-sotigalimab-apx005m-in-participants-with-untreated-metastatic-pancreatic-adenocarcinoma-phase-2-final-resul/ 2023-08-30T10:39:32+00:00 https://pyxisoncology.com/resource/innate-immunotherapy-during-neoadjuvant-therapy-for-rectal-cancer-to-elucidate-local-and-systemic-therapeutic-response/ 2023-08-30T10:40:19+00:00 https://pyxisoncology.com/resource/phase-ii-of-cd40-agonistic-antibody-sotigalimab-apx005m-in-combination-with-nivolumab-in-subjects-with-metastatic-melanoma-with-confirmed-disease-progression-on-anti-pd-1-therapy/ 2023-08-30T10:40:58+00:00 https://pyxisoncology.com/resource/multi-omic-multi-parameter-circulating-biomarker-analysis-in-chemoimmunotherapy-combinations-identifies-unique-immune-activation-signatures-in-the-pancreatic-cancer-setting/ 2023-08-30T10:41:30+00:00 https://pyxisoncology.com/resource/elucidating-factors-of-therapeutic-response-to-immunotherapy-combined-with-neoadjuvant-radiation-therapy-for-rectal-cancer/ 2023-08-30T10:42:05+00:00 https://pyxisoncology.com/resource/intratumoral-cd40-agonist-sotigalimab-apx005m-with-pembrolizumab-induces-broad-innate-and-adaptive-immune-activation-in-local-and-distant-tumors-in-metastatic-melanoma/ 2023-08-30T10:42:41+00:00 https://pyxisoncology.com/resource/distinct-biosignatures-associate-with-survival-after-chemoimmunotherapy-in-a-randomized-three-arm-phase-ii-study-in-patients-with-metastatic-pancreatic-cancer/ 2023-08-30T10:43:15+00:00 https://pyxisoncology.com/resource/use-of-high-dimensional-and-spatial-immune-profiling-to-explore-sotigalimab-cd40-agonist-activation-of-antigen-presenting-cells-and-t-cells-in-the-tumor-microenvironment-in-patients-with-esopha/ 2023-08-30T10:44:56+00:00 https://pyxisoncology.com/resource/a-phase-2-trial-with-a-safety-lead-in-to-evaluate-the-addition-of-sotigalimab-a-cd40-agonistic-monoclonal-antibody-to-standard-of-care-doxorubicin-for-the-treatment-of-advanced-sarcoma/ 2023-08-30T10:46:16+00:00 https://pyxisoncology.com/resource/tissue-assessment-of-theraprutic-responses-to-neoadjuvant-scrt-with-and-without-anit-cd40-immunotherapy-sotigalimab-sotiga-in-rectal-cancer/ 2023-09-18T09:24:16+00:00 https://pyxisoncology.com/resource/intratumoral-sotigalimab-with-pembrolizumab-activates-antigen-presenting-cells-and-induces-local-and-distant-anti-tumor-responses-in-first-line-metastatic-melanoma-results-of-a-phase-i-ii-study/ 2023-09-18T09:30:53+00:00 https://pyxisoncology.com/resource/a-multicenter-phase-2-study-of-sotigalimab-cd40-agonist-in-combination-with-neoadjuvant-chemoradiation-for-resectable-esophageal-and-gastroesophageal-junction-gej-cancers/ 2023-09-18T09:32:36+00:00 https://pyxisoncology.com/resource/intratumoral-cd40-agonist-apx005m-in-combination-with-pembrolizumab-induces-broad-innate-and-adaptive-immune-activation-in-local-and-distant-tumors-in-cpi-treatment-naive-metastatic-melanoma/ 2023-09-18T09:38:23+00:00 https://pyxisoncology.com/resource/phase-i-ii-dose-escalation-and-expansion-study-of-image-guided-intratumoral-apx005m-in-combination-with-systemic-pembrolizumab-in-treatment-naive-metastatic-melanoma-patients/ 2023-09-18T09:40:26+00:00 https://pyxisoncology.com/resource/cd40-agonism-remodels-the-tumor-immune-microenvironment-in-locally-advanced-esophageal-gastroesophageal-junction-cancer-poster-number-1361/ 2023-11-08T15:19:15+00:00 https://pyxisoncology.com/resource/pyx-102-an-anti-klrg1-antibody-enhances-cytotoxic-activity-of-cd8-t-cells-from-pbmc-and-human-tumor-samples-by-blocking-the-interaction-between-klrg1-and-cadherins-poster-number-572/ 2023-11-08T15:19:21+00:00 https://pyxisoncology.com/resource/first-in-human-open-label-multicenter-phase-1-clinical-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-anti-siglec-15-pyx-106-in-subjects-with-advanced-solid-t/ 2023-11-08T15:19:27+00:00 https://pyxisoncology.com/resource/a-first-in-human-phase-1-clinical-study-evaluating-safety-tolerability-pharmacokinetics-pharmacodynamics-and-efficacy-of-the-edbfn-targeting-adc-pyx-201-in-participants-with-advanced-solid-tumors/ 2023-11-08T15:19:34+00:00 https://pyxisoncology.com/resource/anti-extra-domain-b-splice-variant-of-fibronectin-antibody-drug-conjugate-eliminates-tumors-with-enhanced-efficacy-when-combined-with-checkpoint-blockade-mol-cancer-ther-2022-sep-6219146/ 2024-04-08T17:56:10+00:00 https://pyxisoncology.com/resource/pf-06804103-a-site-specific-anti-her2-antibody-drug-conjugate-for-the-treatment-of-her2-expressing-breast-gastric-and-lung-cancers-mol-cancer-ther-2020-oct19102068-2078/ 2024-04-08T18:50:57+00:00 https://pyxisoncology.com/resource/safety-and-tolerability-of-a-novel-anti-her2-antibody-drug-conjugate-pf-06804103-in-patients-with-her2-expressing-solid-tumors-a-phase-1-dose-escalation-study-mol-cancer-ther-2023-oct-22/ 2024-04-08T18:55:07+00:00 https://pyxisoncology.com/resource/pyx-201-edbfn-is-an-attractive-target-in-oncology-insights-from-protein-expression-analysis-of-solid-tumors-abstract-number-2908/ 2024-04-09T08:32:45+00:00 https://pyxisoncology.com/resource/gene-expression-correlation-of-immune-checkpoint-molecules-siglec-15-and-pd-l1-varies-widely-by-cancer-indication/ 2024-04-09T10:57:08+00:00 https://pyxisoncology.com/resource/pyx-201-a-stroma-targeting-adc-composed-of-an-anti-edbfn-antibody-conjugated-to-auristatin0101-demonstrates-strong-anti-tumor-efficacy-across-multiple-human-cancer-indications-in-pre-clinical-pdx-t/ 2024-05-15T09:49:54+00:00 https://pyxisoncology.com/resource/extracellular-proteolytic-cleavage-of-peptide-linked-antibody-drug-conjugates-promotes-bystander-killing-of-cancer-cells-abstract-number-4837/ 2024-05-15T10:07:52+00:00 https://pyxisoncology.com/resource/sarcomas-express-extra-domain-b-of-fibronectin-and-preclinical-patient-derived-xenograft-models-of-several-sarcoma-subtypes-are-sensitive-to-the-stroma-targeting-antibody-drug-conjugate-pyx-201-abst/ 2024-12-02T16:36:09+00:00 https://pyxisoncology.com/resource/associations-of-the-immunomodulatory-molecule-siglec-15-gene-and-protein-expression-to-immune-gene-signatures-as-a-potential-biomarker-for-siglec-15-targeted-therapy-in-non-small-cell-lung-cancer-ab/ 2024-12-02T16:36:20+00:00 https://pyxisoncology.com/resource/characterization-and-prevalence-of-the-novel-immunomodulatory-protein-siglec-15-expression-in-tumor-cells-and-macrophages-across-multiple-solid-tumor-indications-abstract-521/ 2024-12-02T16:36:32+00:00 https://pyxisoncology.com/resource/pyx-106-a-highly-differentiated-anti-siglec-15-monoclonal-antibody-reverses-siglec-15-mediated-immune-suppression-and-enhances-cytotoxic-activity-in-human-lymphocytes-abstract-567/ 2024-12-02T16:36:41+00:00 https://pyxisoncology.com/resource/quantitation-of-total-antibody-tab-from-antibody-drug-conjugate-adc-pyx-201-in-rat-and-monkey-plasma-using-an-enzyme-linked-immunosorbent-assay-elisa-and-its-application-in-preclinical-studies/ 2025-04-01T09:22:05+00:00 https://pyxisoncology.com/resource/quantification-of-antibody-drug-conjugate-pyx-201-in-rat-and-monkey-plasma-via-elisa-and-its-application-in-preclinical-studies-bioanalysis-2023-jan15143-52/ 2025-04-01T09:22:22+00:00 https://pyxisoncology.com/resource/bioanalysis-of-an-antibody-drug-conjugate-adc-pyx-201-in-human-plasma-using-a-hybrid-immunoaffinity-lc-ms-ms-approach-j-chromatogr-b-analyt-technol-biomed-life-sci-2023-may-151223123715/ 2025-04-01T09:23:11+00:00 https://pyxisoncology.com/resource/a-sensitive-and-rapid-lc-ms-ms-assay-for-quantitation-of-free-payload-aur0101-from-antibody-drug-conjugate-adc-pyx-201-in-human-plasma-j-chromatogr-b-analyt-technol-biomed-life-sci-2023-jul-15122/ 2025-04-01T09:23:49+00:00 https://pyxisoncology.com/resource/development-and-validation-of-a-hybrid-immunoaffinity-lc-ms-ms-assay-for-quantitation-of-total-antibody-tab-from-an-antibody-drug-conjugate-adc-pyx-201-in-human-plasma-j-chromatogr-b-anal/ 2025-04-01T09:24:21+00:00 https://pyxisoncology.com/resource/a-sensitive-lc-ms-ms-assay-to-quantitate-free-payload-aur0101-from-adc-pyx-201-in-rat-and-monkey-plasma-bioanalysis-2023-jul1514833-843/ 2025-04-01T09:30:32+00:00 https://pyxisoncology.com/resource/a-phase-1-2-study-of-a-first-in-class-non-cellular-antibody-drug-conjugate-micvotabart-pelidotin-micvo-in-combination-with-pembrolizumab-in-select-advanced-solid-tumors-abstract-number/ 2025-10-22T10:53:15+00:00 https://pyxisoncology.com/resource/phase-1-expansion-study-of-the-first-in-concept-extracellular-antibody-drug-conjugate-adc-micvotabart-pelidotin-micvo-in-patients-with-select-advanced-solid-tumors-abstract-number-103/ 2025-10-22T10:55:23+00:00 https://pyxisoncology.com/resource/histological-biomarker-analysis-of-nonclinical-and-baseline-tumor-samples-from-the-phase-1-dose-escalation-study-using-micvotabart-pelidotin-micvo-in-advanced-solid-tumors-abstract-number/ 2025-10-22T10:55:38+00:00 https://pyxisoncology.com/resource/first-in-human-study-of-the-first-in-class-non-cellular-targeting-antibody-drug-conjugate-adc-micvotabart-pelidotin-micvo-in-patients-with-select-solid-tumors-abstract-number-965/ 2025-10-22T10:55:53+00:00 https://pyxisoncology.com/resource/longitudinal-changes-in-circulating-tumor-dna-in-a-phase-1-dose-escalation-study-of-micvotabartpelidotin-a-first-in-human-adc-targeting-edbfn-abstract-number-1004/ 2025-10-22T10:56:11+00:00 https://pyxisoncology.com/resource/micvotabart-pelidotin-a-non-cellular-targeting-adc-remodels-the-tumor-microenvironment-in-tumors-from-participants-in-a-phase-1-dose-escalation-study-abstract-number-a113/ 2025-10-23T13:16:34+00:00 https://pyxisoncology.com/resource/mouse-analog-of-micvotabart-pelidotin-sensitizes-a-refractory-syngeneic-breast-cancer-model-to-anti-pd1-therapy-abstract-number-a115/ 2025-10-23T13:16:43+00:00 https://pyxisoncology.com/resource/development-of-multiplex-immunofluorescence-workflows-for-characterizing-tumor-immune-and-stromal-compartments-for-pharmacodynamic-assessments-of-solid-tumors-abstract-number-a117/ 2025-10-23T13:16:51+00:00 https://pyxisoncology.com/resource/characterization-of-micvotabart-pelidotin-target-binding-properties-and-extracellular-payload-release-abstract-number-a116/ 2025-10-23T13:16:58+00:00 https://pyxisoncology.com/resource/micvotabart-pelidotin-an-adc-targeting-non-cellular-edbfn-induces-an-immune-response-in-tumors-from-participants-in-a-phase-1-dose-escalation-study-abstract-number-a114/ 2025-10-23T13:17:21+00:00 https://pyxisoncology.com/resource/micvotabart-pelidotin-induces-immunogenic-cell-death-markers-and-activates-tumor-immune-cells-in-pre-clinical-studies-abstract-number-a112/ 2025-10-23T13:17:28+00:00 https://pyxisoncology.com/resource/a-phase-1-2-study-of-a-first-in-class-non-cellular-antibody-drug-conjugate-micvotabart-pelidotin-micvo-in-combination-with-pembrolizumab-in-select-advanced-solid-tumors/ 2025-11-10T13:07:35+00:00 https://pyxisoncology.com/resource/the-combination-of-anti-pd1-and-a-mouse-analog-of-pyx-201-an-antibody-drug-conjugate-targeting-the-extra-domain-b-splice-variant-of-fibronectin-edbfn-shows-greater-anti-tumor-efficacy-than-either/ 2026-01-16T15:08:21+00:00 https://pyxisoncology.com/resource/evaluation-of-pyx-201-an-edbfn-targeting-adc-in-a-comprehensive-pdx-mini-trial-study-enables-identification-of-gene-signatures-associated-with-anti-tumor-activity-abstract-number-3120/ 2026-01-16T15:09:26+00:00 https://pyxisoncology.com/resource/anti-tumor-activity-of-micvotabart-pelidotin-is-associated-with-enzyme-gene-expression-in-patient-derived-xenograft-sarcoma-models-abstract-2165379/ 2026-01-16T15:16:13+00:00 https://pyxisoncology.com/resource/validation-of-anti-adc-assays-with-ada-characterization-to-support-micvotabart-pelidotin-clinical-studies-p15/ 2026-01-16T15:38:21+00:00 https://pyxisoncology.com/resource/detection-of-anti-drug-antibodies-adas-to-an-antibody-drug-conjugate-adc-pyx-201-in-human-plasma-using-a-novel-electrochemiluminescence-ecl-immunoassay/ 2026-04-03T15:37:20+00:00 https://pyxisoncology.com/resource/mouse-analog-of-micvotabart-pelidotin-an-antibody-drug-conjugate-targeting-extradomain-b-of-fibronectin-demonstrates-antitumor-efficacy-in-an-immunotherapy-refractory-syngeneic-head-and-neck-squamou/ 2026-04-23T09:13:02+00:00 https://pyxisoncology.com/resource/development-of-a-novel-immunohistochemistry-assay-to-characterize-extradomain-b-of-fibronectin-edbfn-protein-expression-in-solid-tumors-laboratory-investigation-2026-106/ 2026-09-15T10:06:47+00:00